Anavex Withdraws EU Application for Blarcamesine After Negative EMA Feedback
Event summary
- Anavex Life Sciences withdrew its EU marketing application for blarcamesine as an add-on therapy for early Alzheimer’s disease on March 25, 2026.
- The withdrawal followed negative feedback from the EMA’s CHMP, which indicated it would not issue a positive opinion at this time.
- Anavex had initially submitted the application in October 2023 after encouragement from the EMA’s SME Office.
- The company plans to gather additional data and conduct further analyses to address the CHMP’s feedback.
- Blarcamesine remains in ongoing clinical development for multiple CNS disorders, including Alzheimer’s, Parkinson’s, and Rett syndrome.
The big picture
Anavex’s withdrawal highlights the challenges of navigating stringent regulatory standards in the EU for novel Alzheimer’s therapies. The decision underscores the need for robust clinical data to meet evolving regulatory expectations, particularly as the biopharmaceutical industry races to address the growing unmet need in neurodegenerative diseases. The setback may also impact investor confidence in Anavex’s ability to secure approvals for its lead candidate, blarcamesine, in key markets.
What we're watching
- Regulatory Strategy
- How Anavex will incorporate CHMP feedback into its next regulatory submission strategy.
- Clinical Data
- Whether additional data will sufficiently address CHMP concerns to support future approval.
- Competitive Positioning
- The pace at which Anavex can advance blarcamesine in other markets or indications amid setbacks in the EU.
Related topics